An expert committee has advised against the adoption of malaria vaccines in India, stating the country does not meet the ...

The R21/Matrix-M malaria vaccine generates nearly identical antibodies as those following a natural infection, helping ...

A novel way to prevent the spread of malaria – a potentially life-threatening disease transmitted through bites from ...

ICMR seeks tech transfer for its anti-malaria vaccine, AdFalciVax, likely taking 6-7 years for readiness, targeting severe malaria caused by P. falciparum.

Rwanda reconsiders malaria vaccines after the first spike in cases since 2016.

When ideology overtakes pragmatism in crafting public policies, it portends danger to society. The recent decision by the ...

Malaria, caused by Plasmodium falciparum, remains a major global health threat, claiming 600,000 lives annually, mostly young ...

ICMR, along with RMRCBB, NIMR, and DBT-NII, is developing AdFalciVax—India’s first recombinant chimeric malaria vaccine. It targets two key stages of Plasmodium falciparum, showing strong ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer vaccine candidate rather than its older sibling. The ...